Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma that develops from B lymphocytes, a type of white blood cell involved in the immune system. It typically begins in the lymph nodes but may also affect the bone marrow, spleen, digestive tract, and blood. MCL often grows more rapidly than some other lymphomas, although its behavior can vary between individuals. Advances in targeted therapies, immunotherapy, and personalized treatment have improved outcomes for many patients.
Mantle cell lymphoma originates from B cells located in the mantle zone of lymph node follicles.
Most cases are associated with a genetic abnormality known as the t(11;14) translocation, which leads to overproduction of the cyclin D1 protein and promotes uncontrolled cell growth.
MCL most commonly affects older adults and is more frequently diagnosed in men than women.
Symptoms may develop gradually and include:
Some people are diagnosed during routine medical testing before noticeable symptoms appear.
The exact cause of MCL is unknown, but factors associated with the disease include:
Unlike some cancers, inherited genetic risk plays a limited role in most cases.
Diagnosis usually involves several specialized tests.
These may include:
These evaluations help confirm the diagnosis and determine the stage of the disease.
Treatment depends on the stage of the lymphoma, symptoms, age, and overall health.
Possible treatment approaches include:
Treatment plans are individualized for each patient.
Regular follow-up appointments help evaluate disease activity and treatment response.
Monitoring may include:
Routine monitoring allows timely adjustments to treatment.
Many people benefit from supportive care throughout treatment.
Healthy practices include:
These measures support overall health alongside medical treatment.
Prompt medical evaluation is recommended if symptoms include:
Early treatment of complications may improve outcomes.
Mantle cell lymphoma is a rare form of non-Hodgkin lymphoma that requires individualized care based on the extent and behavior of the disease. Modern treatment options, including targeted therapies, immunotherapy, chemotherapy, stem cell transplantation, and cellular therapies, have expanded the possibilities for long-term disease control. Early diagnosis, personalized treatment, and regular follow-up with a hematology and oncology team are important for achieving the best possible outcomes.